Sisram Medical's China Manufacturing Base Officially Enters Production as First Domestically Produced Alma Rejuve Rolls Off the Line

BEIJING — On a humid morning in late June, the first domestically produced Alma Rejuve energy-based device rolled off the production line at a newly completed manufacturing facility in Miyun district, marking a milestone for Sisram (1696.HK), the medical aesthetics subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

The June 29 announcement signals more than a ribbon-cutting ceremony. It represents the Israel-headquartered company's most ambitious attempt yet to transplant its mature manufacturing playbook into Chinese soil — and to do so at scale.

The Miyun base, co-built by Sisram's wholly owned Tianjin subsidiary and Beijing-based Xingmai Taike Medical Technology, draws directly from the company's Israeli facilities — the same production processes, quality control standards, and decades of energy-based device expertise that have been validated in markets around the world. But this isn't a copy-paste operation. The new facility represents what company executives describe as an "iteration upgrade," with freshly configured production lines designed to leverage China's supply chain advantages and Fosun Pharmaceutical's established manufacturing management systems.

The Localization Play

For Sisram, the China production base is the centerpiece of a localization strategy that has moved from planning to full operational deployment. The Alma Rejuve — already a recognized brand in domestic aesthetic clinics — became the inaugural product of this Made-in-China chapter. The device, known for its anti-aging and skin-rejuvenation capabilities, has been widely adopted by clinical institutions and end consumers alike. Domestic production, the company argues, will tighten supply chains, accelerate delivery timelines, and improve after-sales responsiveness.

The strategic logic extends beyond cost arbitrage. By embedding manufacturing within its largest growth market, Sisram aims to close the loop between R&D, production, sales, and service — creating an integrated value chain that can respond to market signals with greater agility.

Asia-Pacific as Growth Engine

Li Jiahong, Sisram's co-CEO and CFO, framed the Miyun facility as the opening act of a broader regional offensive. "The Asia-Pacific region is our core revenue growth engine," Li said in a statement accompanying the announcement. "Demand for energy-based devices in the region continues to be robust. This forward-looking capacity layout will fully capture the momentum of market growth."

The executive added that the company is building what he called a "more resilient, more competitive local industrial ecosystem" — one designed to respond to market demands with greater agility and deliver products and innovations at a faster pace. The goal, he said, is to inject greater stability and operational efficiency into the company's global supply chain.

Once fully operational, the Beijing facility will serve not only domestic demand but also function as a strategic hub for the broader Asia-Pacific region — handling capacity expansion, logistics coordination, and the transfer of cutting-edge R&D into commercial products.

Beyond Hardware

The timing coincides with a broader shift in China's medical aesthetics market — from single-treatment models toward full-cycle management approaches. Sisram is betting that the synergy between its energy-based devices and injectable filler products, combined with localized production, will unlock new combination effects and deliver more accessible, higher-quality solutions to Chinese consumers.

Whether this bet pays off depends on execution. The company has the blueprint. It has the supply chain. And now, it has the factory floor. The next question is whether it can translate manufacturing capability into sustained market share gains in an increasingly competitive landscape.